Barclays Initiates Coverage On Forte Biosciences with Overweight Rating, Announces Price Target of $74
FORTE BIOSCIENCES INC
FORTE BIOSCIENCES INC FBRX | 0.00 |
Barclays analyst Etzer Darout initiates coverage on Forte Biosciences (NASDAQ:
FBRX) with a Overweight rating and announces Price Target of $74.
